Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is projected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($2.1850) per share and revenue of $0.1790 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.36 million. On average, analysts expect Seres Therapeutics to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Seres Therapeutics Price Performance

Shares of MCRB opened at $4.83 on Monday. Seres Therapeutics has a 12 month low of $4.59 and a 12 month high of $29.98. The stock has a fifty day moving average price of $6.44 and a 200 day moving average price of $8.78. The company has a market cap of $46.75 million, a P/E ratio of -0.93 and a beta of 0.20.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MCRB shares. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Wall Street Zen raised shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Finally, HC Wainwright began coverage on shares of Seres Therapeutics in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $17.00.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its position in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 21,679 shares during the period. Invesco Ltd. increased its holdings in shares of Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 89,995 shares during the period. Bank of America Corp DE increased its holdings in shares of Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 5,157 shares during the period. Barclays PLC raised its stake in shares of Seres Therapeutics by 427.8% during the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 6,024 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Seres Therapeutics during the fourth quarter valued at about $190,000. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.